GSK CEO Walm­s­ley is re­or­ga­niz­ing R&D, drop­ping drugs and adding a new fo­cus on can­cer re­search

Just days af­ter rush­ing Dana-Far­ber chief Lau­rie Glim­ch­er on­to the board at Glax­o­SmithK­line $GSK, new CEO Em­ma Walm­s­ley is mak­ing her move to re­or­ga­nize the pipeline. Her plan calls for a ma­jor R&D cull, drop­ping 30 de­vel­op­ment projects and adding can­cer and im­muno-in­flam­ma­to­ry dis­eases to its list of top R&D pri­or­i­ties — which will con­sume the li­on’s share of its bud­get.

Em­ma Walm­s­ley

In a state­ment out ear­ly Wednes­day, GSK out­lined plans to part­ner out or sim­ply drop 30 pre­clin­i­cal and clin­i­cal pro­grams, stream­lin­ing R&D and oth­er op­er­a­tions in the glob­al op­er­a­tion as the com­pa­ny looks for about $1.3 bil­lion in sav­ings by 2020. Rare dis­ease drugs in par­tic­u­lar ap­pear to be on the chop­ping block while a list of as­sets that are be­ing dropped from the pipeline in­cludes sirukum­ab, its dis­ap­point­ing rheuma­toid arthri­tis drug now un­der reg­u­la­to­ry re­view and part­nered with J&J $JNJ.

You can see the full list be­low.

The move puts GSK back in play as sev­er­al top bio­phar­ma com­pa­nies look to shake up their R&D or­ga­ni­za­tions and start to strike new deals. And the phar­ma gi­ant’s re­turn to the deal ta­ble will quick­ly earn close at­ten­tion from a long list of ri­vals. More big play­ers are al­so like­ly to fol­low suit, mark­ing a turn­ing point for bio­phar­ma as a slate of new CEOs look to put their dis­tinc­tive stamp on prod­uct de­vel­op­ment.

The plan at Glax­o­SmithK­line now is to re­serve about 80% of its an­nu­al multi­bil­lion-dol­lar bud­get for two main­stay dis­ease fields — res­pi­ra­to­ry and HIV/in­fec­tious dis­eases — while ex­am­in­ing the “po­ten­tial” ad­di­tion of can­cer and im­muno-in­flam­ma­tion. GSK spent $4.5 bil­lion on R&D, putting it among the top 15 in the in­dus­try.

The phar­ma gi­ant al­so plans to get its busi­ness de­vel­op­ment team back to the bar­gain­ing ta­ble af­ter a long ab­sence in search of new, pri­mar­i­ly ear­ly-stage deals.

Walm­s­ley in­her­it­ed one of the weak­est R&D groups in Big Phar­ma when she took the helm in April. De­spite sig­nif­i­cant progress in HIV and vac­cines, phar­ma R&D lan­guished af­ter a pe­ri­od marked by some high-pro­file flame­outs in Phase III de­vel­op­ment. Now the CEO wants to use the stream­lin­ing to set up a re­vival for the phar­ma re­search group.

From their quar­ter­ly state­ment:

In its Phar­ma­ceu­ti­cals pipeline, GSK has de­vel­oped a pri­or­i­ty list of as­sets to in­vest be­hind. This pri­or­i­ty list will evolve as da­ta reads out. The Group has al­so set a tar­get to de­ploy over time 80% of its Phar­ma­ceu­ti­cals R&D cap­i­tal to pri­or­i­ty as­sets in two cur­rent ther­a­py ar­eas: Res­pi­ra­to­ry and HIV/in­fec­tious dis­eases; and two po­ten­tial ar­eas: On­col­o­gy and Im­muno-in­flam­ma­tion. Sig­nif­i­cant da­ta is ex­pect­ed from these pri­or­i­ty as­sets over the next three years which will be used to in­form R&D in­vest­ment de­ci­sions and how best to gen­er­ate val­ue from these as­sets. GSK al­so ex­pects to pur­sue dis­ci­plined busi­ness de­vel­op­ment to aug­ment its ear­ly-stage pipeline in these pri­or­i­ty ar­eas.

Now in the spot­light at GSK: A range of Phase I and Phase II can­cer drugs, in­clud­ing its mid-stage pro­gram part­nered with Adap­ti­m­mune $ADAP.

J&J says that GSK’s de­ci­sion to bail out on sirukum­ab leaves them in charge of world­wide roll­out, and they have no plans to change course now. In a state­ment to End­points News, the com­pa­ny not­ed:

Our pri­or­i­ty is work­ing with Health Au­thor­i­ties in the U.S., Eu­rope, Japan and many oth­er coun­tries to bring this nov­el an­ti-IL-6 mon­o­clon­al an­ti­body to RA pa­tients.  We are con­tin­u­ing with launch prepa­ra­tions in EMEA and Asia Pa­cif­ic through our world-class Janssen Im­munol­o­gy or­ga­ni­za­tion, and we are al­so ex­plor­ing the best op­por­tu­ni­ties to bring this im­por­tant new med­i­cine to pa­tients in the ge­o­gra­phies that will re­turn to Janssen.

The move at GSK mir­rors the same ba­sic strat­e­gy that Michel Vounatsos and Dave Ricks an­nounced yes­ter­day for Bio­gen and Eli Lil­ly. Both have been lay­ing plans to “stream­line” op­er­a­tions and de­vote more time to new projects that can whip up some ex­cite­ment among the in­vestor crowd. Lil­ly al­so is drop­ping can­cer projects — while GSK looks to add to what’s left of its on­col­o­gy group fol­low­ing a big trade­off with No­var­tis.

These moves will cre­ate dozens of new busi­ness op­por­tu­ni­ties among biotech play­ers look­ing for new as­sets to pick over. Typ­i­cal­ly these projects go for on­ly small amounts of up­front cash. And it al­so adds new play­ers to the deal ta­ble, ready to spend cash and part­ner on more drugs.

GSK sig­naled this move re­cent­ly af­ter it re­cruit­ed Glim­ch­er to its board. The im­muno-on­col­o­gy ex­pert joined the board’s sci­ence team and can of­fer some key in­sights gleaned from years on the board at Bris­tol-My­ers Squibb.


From the GSK pre­sen­ta­tion:

Hal Barron, GSK

Break­ing the death spi­ral: Hal Bar­ron talks about trans­form­ing the mori­bund R&D cul­ture at GSK in a crit­i­cal year for the late-stage pipeline

Just ahead of GlaxoSmithKline’s Q2 update on Wednesday, science chief Hal Barron is making the rounds to talk up the pharma giant’s late-stage strategy as the top execs continue to woo back a deeply skeptical investor group while pushing through a whole new R&D culture.

And that’s not easy, Barron is quick to note. He told the Financial Times:

I think that culture, to some extent, is as hard, in fact even harder, than doing the science.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,200+ biopharma pros reading Endpoints daily — and it's free.

Some Big Phar­mas stepped up their game on da­ta trans­paren­cy — but which flunked the test?

The nonprofit Bioethics International has come out with their latest scorecard on data transparency among the big biopharmas in the industry — flagging a few standouts while spotlighting some laggards who are continuing to underperform.

Now in its third year, the nonprofit created a new set of standards with Yale School of Medicine and Stanford Law School to evaluate the track record on trial registration, results reporting, publication and data-sharing practice.

Busy Gilead crew throws strug­gling biotech a life­line, with some cash up­front and hun­dreds of mil­lions in biobucks for HIV deal

Durect $DRRX got a badly needed shot in the arm Monday morning as Gilead’s busy BD team lined up access to its extended-release platform tech for HIV and hepatitis B.

Gilead, a leader in the HIV sector, is paying a modest $25 million in cash for the right to jump on the platform at Durect, which has been using its technology to come up with an extended-release version of bupivacaine. The FDA rejected that in 2014, but Durect has been working on a comeback.

In­tec blitzed by PhI­II flop as lead pro­gram fails to beat Mer­ck­'s stan­dard com­bo for Parkin­son’s

Intec Pharma’s $NTEC lead drug slammed into a brick wall Monday morning. The small-cap Israeli biotech reported that its lead program — coming off a platform designed to produce a safer, more effective oral drug for Parkinson’s — failed the Phase III at the primary endpoint.

Researchers at Intec, which has already seen its share price collapse over the past few months, says that its Accordion Pill-Carbidopa/Levodopa failed to prove superior to Sinemet in reducing daily ‘off’ time. 

Cel­gene racks up third Ote­zla ap­proval, heat­ing up talks about who Bris­tol-My­ers will sell to

Whoever is taking Otezla off Bristol-Myers Squibb’s hands will have one more revenue stream to boast.

The drug — a rising star in Celgene’s pipeline that generated global sales of $1.6 billion last year — is now OK’d to treat oral ulcers associated with Behçet’s disease, a common symptom for a rare inflammatory disorder. This marks the third FDA approval for the PDE4 inhibitor since 2014, when it was greenlighted for plaque psoriasis and psoriatic arthritis.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,200+ biopharma pros reading Endpoints daily — and it's free.

Francesco De Rubertis

Medicxi is rolling out its biggest fund ever to back Eu­rope's top 'sci­en­tists with strange ideas'

Francesco De Rubertis built Medicxi to be the kind of biotech venture player he would have liked to have known back when he was a full time scientist.

“When I was a scientist 20 years ago I would have loved Medicxi,’ the co-founder tells me. It’s the kind of place run by and for investigators, what the Medicxi partner calls “scientists with strange ideas — a platform for the drug hunter and scientific entrepreneur. That’s what I wanted when I was a scientist.”

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,200+ biopharma pros reading Endpoints daily — and it's free.

Af­ter a decade, Vi­iV CSO John Pot­tage says it's time to step down — and he's hand­ing the job to long­time col­league Kim Smith

ViiV Healthcare has always been something unique in the global drug industry.

Owned by GlaxoSmithKline and Pfizer — with GSK in the lead as majority owner — it was created 10 years ago in a time of deep turmoil for the field as something independent of the pharma giants, but with access to lots of infrastructural support on demand. While R&D at the mother ship inside GSK was souring, a razor-focused ViiV provided a rare bright spot, challenging Gilead on a lucrative front in delivering new combinations that require fewer therapies with a more easily tolerated regimen.

They kept a massive number of people alive who would otherwise have been facing a death sentence. And they made money.

And throughout, John Pottage has been the chief scientific and chief medical officer.

Until now.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,200+ biopharma pros reading Endpoints daily — and it's free.

Vlad Coric (Biohaven)

In an­oth­er dis­ap­point­ment for in­vestors, FDA slaps down Bio­haven’s re­vised ver­sion of an old ALS drug

Biohaven is at risk of making a habit of disappointing its investors.

Late Friday the biotech $BHVN reported that the FDA had rejected its application for riluzole, an old drug that they had made over into a sublingual formulation that dissolves under the tongue. According to Biohaven, the FDA had a problem with the active ingredient used in a bioequivalence study back in 2017, which they got from the Canadian drugmaker Apotex.

Apotex, though, has been a disaster ground. The manufacturer voluntarily yanked the ANDAs on 31 drugs — in late 2017 — after the FDA came across serious manufacturing deficiencies at their plants in India. A few days ago, the FDA made it official.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,200+ biopharma pros reading Endpoints daily — and it's free.

Chas­ing Roche's ag­ing block­buster fran­chise, Am­gen/Al­ler­gan roll out Avastin, Her­ceptin knock­offs at dis­count

Let the long battle for biosimilars in the cancer space begin.

Amgen has launched its Avastin and Herceptin copycats — licensed from the predecessors of Allergan — almost two years after the FDA had stamped its approval on Mvasi (bevacizumab-awwb) and three months after the Kanjinti OK (trastuzumab-anns). While the biotech had been fielding biosimilars in Europe, this marks their first foray in the US — and the first oncology biosimilars in the country.